Skip to main content

Table 1 Baseline characteristics of HCM patients and controls

From: In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy

 

HCM (n = 16)

Controls (n = 14)

p-value

Age (y)

47 ± 14

48 ± 15

0.82

Gender (m/f)

12/4

8/6

0.44

Mutation in sarcomeric gene

- MYBPC3 (6, 38%)

  

- MYH7 (1, 6%)

 

- TNNT2 (2, 13%)

 

- Excluded (3, 19%)

- Excluded (11, 79%)

- Unknown (4, 25%)

- Unknown (3, 21%)

Systolic BP (mmHg)

132 ± 12

132 ± 26

0.96

Diastolic BP (mmHg)

75 ± 11

77 ± 9

0.67

Heart rate (BPM)

63 ± 13

68 ± 10

0.21

BSA (kg/m2)

2.0 ± 0.17

1.9 ± 0.19

0.10

Medication

Beta-blocker (8, 50%)

None

 

Ca-antagonist (1, 6%)

Hematocrit (L/L)

0.45 ± 0.04.

0.42 ± 0.02

0.007

  1. MYBPC3, MYH7 and TNNT2 genes encoding the sarcomeric proteins myosin binding protein C, myosin heavy chain and troponin T, respectively. BP = blood pressure. BPM = beats per minute. BSA = body surface area.